Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure
W.H. Wilson Tang, MD, FACC*,*,
Wilson Tong, MSc*,
Richard W. Troughton, MBBS ,
Maureen G. Martin, RDCS*,
Kevin Shrestha, AB*,
Allen Borowski, RDCS*,
Sue Jasper, BSN*,
Stanley L. Hazen, MD, PhD, FACC*,1 and
Allan L. Klein, MD, FACC*
* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Christchurch School of Medicine, Christchurch, New Zealand.
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Analysis of All-Cause Death, Cardiac Transplantation, or Heart Failure Hospitalization
–/+MPO = first tertile ( 271 pM) versus second and third tertile (>271 pM) plasma MPO levels; –/+BNP = below-median versus above-median plasma BNP levels (median = 65 pg/ml). BNP = B-type natriuretic peptide; MPO = myeloperoxidase.
|
|
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Adverse Event Rate and Corresponding Hazard Ratios for Subgroups
Hazard ratios are calculated relative to the subgroup with the lowest risk (hazard ratio = 1.0). HF = heart failure; LVEF = left ventricular ejection fraction; MPO = myeloperoxidase.
|
|
|
